<SEC-DOCUMENT>0001420720-26-000014.txt : 20260804
<SEC-HEADER>0001420720-26-000014.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804070535
ACCESSION NUMBER:		0001420720-26-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260731
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iBio, Inc.
		CENTRAL INDEX KEY:			0001420720
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262797813
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35023
		FILM NUMBER:		261235417

	BUSINESS ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737
		BUSINESS PHONE:		302 355-0650

	MAIL ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iBioPharma, Inc.
		DATE OF NAME CHANGE:	20080806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	InB:Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20071210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ibio-20260722x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.4.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/4/2026 10:58:20 AM -->
<!-- iXBRL Library version: 1.0.9655.2621 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:ibio="http://ibioinc.com/20260722" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>iBio,&#160;Inc._July 31, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityCentralIndexKey" id="Tc_TRemXnGIkUyzH4eBtpI6Mw_2_1">0001420720</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:AmendmentFlag" id="Tc_tePOu3hjS0a2UTFgdSUQEg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ibio-20260722.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-07-22</xbrli:startDate><xbrli:endDate>2026-07-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_98636807_312f_445f_a643_3320022e7084"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:DocumentType" id="Narr_NYqXz3kl00CDd1ehxFMz4A"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;">Date of Report (date of earliest event reported): <ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_6Emtbrp0dUSNXqaifQ2FFw"><b style="font-weight:bold;">July 31, 2026</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityRegistrantName" id="Narr_UnJempJLJ0uG7JTXOCyNPw"><b style="font-weight:bold;">iBio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(Exact name of registrant as specified in charter)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Narr_qzNckg8bmkGO2T5aP1Gc2w"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(State or other jurisdiction of incorporation)</i></p><a id="_635f163a_2c1e_4224_a411_0cb28da822b2"></a><a id="Tc_soGg3EPg8EWTfori7RMYCA_2_0"></a><a id="Tc_elby5BK--0mOzVbf1cSZMA_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityFileNumber" id="Tc_ZXshJUAQvEOnOpLY14MsGA_1_0"><b style="font-weight:bold;">001-35023</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityTaxIdentificationNumber" id="Tc_ih291esrM0OJQA_X0O01SA_1_1"><b style="font-weight:bold;">26-2797813</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Commission File Number)</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(IRS Employer Identification No.)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityAddressAddressLine1" id="Narr_jmHcOE4zJEyV21BkBPGUYw"><b style="font-weight:bold;">11750 Sorrento Valley Road, Suite 200</b></ix:nonNumeric></p><a id="Narr_8OpWsz18z0WxtVjWwtIdqg"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:EntityAddressCityOrTown" id="Narr_wGyobNkuB0qSAXJ-HXgT9w"><b style="font-weight:bold;">San</b></ix:nonNumeric><b style="font-weight:bold;"> Diego, California 92121</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(Address of principal executive offices and zip code)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:CityAreaCode" id="Narr_8HPK_as8VUeJ2PA_yabI0Q"><b style="font-weight:bold;">979</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:LocalPhoneNumber" id="Narr_Mgp1Unz9LUasO80oDFfP6w"><b style="font-weight:bold;">446-0027</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(Registrant&#8217;s telephone number including area code)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(Former Name and Former Address)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</p><a id="_Hlk83619405"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 9pt 18pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_m7FIA7vW3UWbxYhDKOCj0Q"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 9pt 18pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_VGRLhBcZNk-Xqk_F3wzcnw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>Soliciting material pursuant to Rule&#160;14a-12(b)&#160;under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:19.45pt;text-indent:-19.45pt;margin:0pt 0pt 9pt 18pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_wBZM11_RnU-XrwOSF0TjVg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:19.45pt;text-indent:-19.45pt;margin:0pt 0pt 9pt 18pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_Y8yk1MX1bkmOS9Fd7dJlNw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_1ec25056_4530_4c68_8457_4e8f5d852e77"></a><a id="Tc_7aXHv9uS_kuErJKlERRw8Q_1_0"></a><a id="Tc_xHpSl1wNG0OE-HlrkrnU4A_1_1"></a><a id="Tc_2ihsEePGpk64qE8JHJ3auA_1_2"></a><a id="Tc_Uq7hwRxPv0ee5Vg2SgVsrw_2_0"></a><a id="Tc_Ivr5dymzVEiRkqGLRJui0Q_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:40.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:20.1%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:38.94%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style=""><td style="vertical-align:top;width:40.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:Security12bTitle" id="Narr_uEQBWNwR90O44mw7pSL4Bw">Common Stock</ix:nonNumeric>, $0.001 par value per share</p></td><td style="vertical-align:top;width:20.1%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" name="dei:TradingSymbol" id="Tc_4E7KL66C7EaTxunfVVskWw_2_1">IBIO</ix:nonNumeric></p></td><td style="vertical-align:top;width:38.94%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The Nasdaq Stock Market LLC</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Emerging growth company &#160;<ix:nonNumeric contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_A1rhiV3JoEaAMfhlPGBjzA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Wingdings';">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bdbf50fb_847b_4c0d_9070_550991b65b51"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item&#160;5.02</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the &#8220;Company&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Dr. Molly Carr, M.D., age 59, is a physician executive with extensive experience in the biotechnology and pharmaceutical industries. Immediately prior to joining the Company, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company (&#8220;Eli Lilly&#8221;) since 2021. In that role, she oversaw clinical development activities for Eli Lilly&#8217;s insulin and glucagon portfolio, including late-stage development programs for efsitora, a once-weekly insulin candidate, as well as other diabetes and metabolic disease therapies. Prior to assuming that position, Dr. Carr served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly from 2018 to 2021, where she led the evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases. Before joining Eli Lilly, Dr. Carr held positions of increasing responsibility at GlaxoSmithKline plc, including Endocrine Scientific Lead, Metabolic Pathways &amp; Cardiovascular R&amp;D Unit, and Global Medical Affairs Lead for albiglutide. Earlier in her career, she served in clinical development and medical leadership roles at CSL Behring and Wyeth LLC and held academic appointments in endocrinology and metabolism at Northwestern University, the University of Washington, and the University of Pennsylvania. Dr. Carr received a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons. She is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the terms of an employment agreement that the Company entered into with Dr. Carr, dated July 31, 2026 (the &#8220;Employment Agreement&#8221;), Dr. Carr will receive an annual base salary of $470,000 and will be eligible to earn an annual target cash bonus equal to 40% of her base salary, based on individual and Company performance criteria established by the Compensation Committee of the Board of Directors. Dr. Carr will also be entitled to participate in the Company&#8217;s employee benefit plans and programs generally available to similarly situated executives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">As an inducement material to Dr. Carr&#8217;s entering into employment with the Company, the Compensation Committee of the Board of Directors approved a non-qualified stock option award to purchase 430,000 shares of the Company&#8217;s common stock (the &#8220;Inducement Award&#8221;). The Inducement Award was granted outside of the Company&#8217;s 2023 Omnibus Incentive Plan (the &#8220;Plan&#8221;), but subject to the terms and conditions of the Company&#8217;s standard form of stock option agreement and, except as otherwise required to qualify as an inducement award, substantially the same terms and conditions applicable to awards granted under the Plan. The Inducement Award was granted on July 31, 2026, has an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date, a term of ten years, and will vest as follows: twenty-five percent (25%) of the shares subject to the Inducement Award will vest on the one-year anniversary of Dr. Carr&#8217;s commencement of employment and the remaining seventy-five percent (75%) will vest in thirty-six (36) substantially equal monthly installments thereafter, subject to Dr. Carr&#8217;s continued service through each applicable vesting date. The Compensation Committee determined that the Inducement Award constituted a material inducement to Dr. Carr&#8217;s acceptance of employment with the Company. The Inducement Award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">If Dr. Carr&#8217;s employment is terminated by the Company without Cause or if she resigns for Good Reason (each as defined in the Employment Agreement), and subject to her execution and non-revocation of a release of claims, she will be entitled to receive severance benefits consisting of (i) continued payment of her base salary for nine months, (ii) a pro rata share of any annual bonus earned during the year of termination based on actual performance, and (iii) Company-paid COBRA premium coverage for nine months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">In addition, if Dr. Carr&#8217;s employment is terminated by the Company without Cause during the period beginning one month prior to, or ending twelve months following, a Sale Event (as defined in the Plan), or if she resigns for Good Reason within twelve months following a Sale Event, then, subject to her execution and non-revocation of a release of claims, she will be entitled to enhanced severance benefits consisting of (i) continued payment of her base salary for twelve months, (ii) a cash payment equal to her target annual bonus for which she would have been eligible during the year of termination, (iii) full vesting acceleration of her outstanding unvested time-based equity awards, and (iv) Company-paid COBRA premium coverage for twelve months. </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">The Employment Agreement also contains customary provisions regarding confidentiality, assignment of intellectual property, non-solicitation of employees and business relationships for one year following termination of employment, non-disparagement, and other customary restrictive covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">There are no family relationships between Dr. Carr and any director or executive officer of the Company, and there are no transactions involving Dr. Carr requiring disclosure under Item 404(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_adb7263a_ed75_45ec_96db_431e704acf89"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.01</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 4, 2026, the Company publicly announced the appointment of Dr. Carr as its Chief Medical Officer and the grant of the Inducement Award described above. A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company is furnishing this Current Report, in part, to satisfy the public disclosure requirements of Nasdaq Listing Rule 5635(c)(4) with respect to the Inducement Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Forward-Looking Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_47484e71_ef9d_462f_8706_c47bb9ca7c72"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:87.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1&#8224;</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20260722xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated July 31, 2026, by and between iBio, Inc. and Molly Carr, MD</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20260722xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Press Release, dated August 4, 2026</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:9pt;">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="background:#ffffff;">The Company has omitted certain portions of this exhibit which are indicated therein by [***] in order to apply confidential treatment. The Company agrees to furnish unredacted copies of these exhibits to the SEC upon request.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_92a91f04_8225_41b7_a71f_364f550a779d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">IBIO, INC.</b></p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 4, 2026</p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marc Banjak</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:38.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marc Banjak</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:38.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ibio-20260722xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.4.0.56--><!--Created on: 8/4/2026 10:58:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:6pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Employment Agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is entered into as of July 31, 2026, by and between iBio, Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio</u>&#8221;), and Molly Carr (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive</u>&#8221;). &#160;The Effective Date of this Agreement shall be July 31, 2026. &#160;In consideration of the premises and mutual covenants contained herein, and intending to be legally bound thereby, the parties agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u>.</p></td></tr></table><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. &#160;The term of this Agreement shall commence on the Effective Date and shall continue until terminated in accordance with the provisions of Section 4 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>&#8221;).</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position</u>. &#160;During the Term, on the terms and subject to the conditions set forth in this Agreement, the Company shall employ the Executive and the Executive shall serve the Company as &#8220;Chief Medical Officer.&#8221; &#160;The Executive shall report to the Company&#8217;s Chief Executive Officer (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u>&#8221;).</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duties</u>. &#160;The Executive shall be responsible for the supervision of the medical affairs and product development functions of the Company, including establishing clinical strategy and development plans for product candidates, and such other duties and responsibilities as may be assigned, from time to time, by and subject to the direction of the CEO, as well as additional responsibilities that are customary for employees performing the Chief Medical Officer function. &#160;In addition, the Executive shall serve at no additional compensation in such executive capacity or capacities with respect to any subsidiary or affiliate of the Company to which she may be assigned, provided that such duties are not inconsistent with those of a Chief Medical Officer. &#160;The Executive shall devote substantially all of the Executive&#8217;s time and attention to the performance of the Executive&#8217;s duties and responsibilities for and on behalf of the Company except as set forth herein or as may be consented to by the CEO. &#160;Executive shall be required to travel to any Company office, including, but not limited to, the facilities in California.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outside Activities</u>. &#160;Notwithstanding anything to the contrary herein, Executive shall be permitted: (i) to serve as a member of the board of directors or advisory board (or their equivalents in the case of a non-corporate entity) of any charitable or philanthropic organization; (ii) to engage in charitable, community or philanthropic activities or any other activities; or (iii) to serve as an executor, trustee or in a similar fiduciary capacity; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided,</u> that the activities set out in the foregoing clauses shall be limited by the Executive so as not to affect, interfere or conflict with, individually or in the aggregate, the performance of the Executive&#39;s duties and responsibilities. &#160;Any outside activities in excess of the foregoing shall require the consent of the CEO.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Policies</u>. &#160;The employment relationship between the parties shall also be subject to the Company&#8217;s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#8217;s sole discretion. &#160;Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Century Gothic';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">At-will Employment</u>. &#160;Subject to the provisions of section 4 of this Agreement, Executive shall be employed on an at-will basis. &#160;Neither this Agreement nor any of the Company&#8217;s policies, practices or procedures constitute an expressed or implied contract of employment for a specific duration of time. &#160;Employment at the Company and its affiliates is a voluntary employment &#8220;at-will&#8221; relationship for no definite period of time which affords either party the right to terminate the relationship at any time for any reason or for no reason at all not prohibited by law.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>. &#160;During the Tern, the Executive shall receive, for all services rendered to the Company pursuant to this Agreement, the following:</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>. &#160;The Employee shall be paid a base salary at the rate of ($475,000.00) per annum (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>&#8221;), less such deductions for withholding taxes required under applicable law or as otherwise authorized by the Executive. The Base Salary shall accrue from and after the Effective Date and shall be payable during the Term in equal periodic installments in accordance with Company&#8217;s then current general salary payment policies. &#160;The Executive&#8217;s Base Salary shall be reviewed from time to time by the Compensation Committee (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Committee</u>&#8221;) of the Board of Directors (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) and may be increased based upon the evaluation of the Executive&#8217;s performance and the compensation policies of the Company in effect at the time of each such review.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bonus</u>. &#160;Executive shall be eligible for a target bonus of 40% of the base salary paid to Executive during the prior fiscal year based upon either the Compensation Committee&#8217;s or the Board&#8217;s assessment of her performance and the performance of the Company during the prior fiscal year. &#160;Unless otherwise stated herein, to earn any bonus, the Executive must be employed by the Company on the day such bonus is paid. &#160;In all events, any bonus awarded pursuant to this Section 3(b) will be paid within 2-1/2 months following the end of the fiscal year for which it is earned.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Grant</u>. The Executive shall receive an initial grant of nonqualified stock options to purchase 430,000 shares of the Company&#8217;s common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u>&#8221;) based on the grant date stock price, as a stand-alone award separate and apart from, and outside of, the Company&#8217;s 2023 Omnibus Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;) that is intended to constitute a non-plan based &#8220;inducement grant&#8221; as described in Nasdaq Listing Rule 5635(c)(4) and shall not constitute an Option granted under the Plan, provided however that the terms, conditions, and definitions set forth in the Plan shall apply to the Option as though the Option had been granted under the Plan, which Option shall be subject to conditions of applicable law and the terms and conditions of an inducement grant agreement. &#160;Such options will vest at the following rates: (1) 25% of the options granted will vest one year following the grant date; and (2) after one year following the grant date, 6.25% of the options granted will vest for each additional 3 months of employment, subject to the conditions of the Plan and inducement grant agreement. &#160;The Executive shall also be eligible for any additional grants of equity compensation from time to time, subject to the approval of the Board, the Plan, and grant agreement issued thereunder.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefits</u>. &#160;During the Term, the Company shall provide the Executive with the following benefits:</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Plans</u>. &#160;The Executive and her dependents (as that term may be defined under the applicable benefit plan(s) of the Company) shall be included, if and to the extent eligible thereunder, in any and all standard benefit plans, programs and policies of the Company provided to similarly situated executives (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefits Plans</u>&#8221;). The Executive acknowledges and agrees that the Benefits Plans may from time to time be modified by the Company as it deems necessary and appropriate.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Paid Time Off</u>. &#160;The Executive shall be entitled to paid vacation, paid holidays and other flexible time off (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FTO</u>&#8221;) for which executives of the Company are generally eligible, in each case consistent with Company policy in effect from time to time.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u>. The Executive shall receive coverage under the Company&#8217;s Directors and Officers Liability Insurance under terms and conditions substantially similar to other executives of the Company. &#160;The Executive acknowledges and agrees that such insurance may from time to time be modified by the Company as it deems necessary and appropriate.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u>. &#160;The Company is authorized to deduct and withhold from the Executive&#8217;s compensation all sums authorized by the Executive or necessary or required (whether by law, court decree, executive order or otherwise), including, but not limited to, social security, income tax withholding and otherwise, and any other amounts required by law or any taxing authority.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>. &#160;The Company shall reimburse the Executive for all reasonable and necessary out-of-pocket expenses incurred by the Executive in connection with the performance of the Executive&#39;s duties and responsibilities hereunder, upon presentment of a valid receipt or other usual and customary documents evidencing such expenses. The Company will reimburse properly substantiated and timely submitted expenses in accordance with Company policy.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>.</p></td></tr></table><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The employment of the Executive hereunder (and this Agreement) shall be terminable as described in Section 2 subject to the provisions of this Section 4.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Mutual Agreement</u>. &#160;The Company and the Executive may, by mutual written agreement, terminate the employment of the Executive hereunder (and this Agreement) at any time, in which case the Executive will be entitled only to the Standard Termination Benefits (as defined in Section 4(i) of this Agreement).</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Company for Cause</u>. &#160; The employment of the Executive hereunder (and this Agreement) shall be terminated (but after the expiration of the cure period described in clause (v) below, if applicable), at the option of the Company, for &#8220;Cause&#8221; (as defined herein), upon written notice to the Executive specifying the subsection(s) of the definition of Cause relied on to support the decision to terminate, in which event the Company shall have no further obligations or liabilities under this Agreement (including, without limitation, Section 3 hereof) except to pay to the Executive the Standard Termination Benefits. &#160;Termination by the Company for Cause shall be effective immediately after the Company gives notice to Executive of Executive&#8217;s termination, unless the Company specifies a later date, in which case, termination</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shall be effective as of such later date; provided that no effective date of termination shall precede the expiration of the cure period described in clause (v) below, if applicable. &#160;For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; means: (i) an act of personal dishonesty in connection with the Executive&#8217;s responsibilities as an employee of the Company that is intended to result in personal enrichment of the Executive; (ii) Executive&#8217;s commission of a felony or other crime involving theft, fraud or moral turpitude which the Company reasonably believes has had or could have a material detrimental effect on the Company&#8217;s reputation or business; (iii) a breach of any fiduciary duty owed to the Company that has, or reasonably could have, a material detrimental effect on the Company&#8217;s reputation or business as determined in good faith by the Company; (iv) willful violations of the Executive&#8217;s obligations to the Company; or (v) the breach by the Executive of any material obligation imposed upon the Executive pursuant to this Agreement or any other material policy of the Company if (in the event such failure is reasonably susceptible of cure) such failure continues uncured for thirty (30) days after written notice specifying in reasonable detail such failure.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Company without Cause</u>. &#160;The employment of the Executive hereunder (and this Agreement) may be terminated at any time, at the option of the Company without Cause. &#160;Termination by the Company without Cause shall be effective immediately after the Company gives notice to Executive of Executive&#8217;s termination, unless the Company specifies a later date, in which case, termination shall be effective as of such later date.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Death of Executive</u>. &#160;This Agreement will terminate automatically upon the death of the Executive, in which event the Company shall have no further obligations or liabilities under this Agreement (including, without limitation, Section 3 hereof) except to pay to the Executive&#8217;s estate or her personal representative, as the case may be, the Standard Termination Benefits.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Disability of Executive</u>. &#160;The employment of the Executive hereunder (and this Agreement) shall be terminated, at the option of the Company, upon not less than thirty (30) days prior written notice to the Executive or her legal representative, as the case may be, in the event the Executive suffers a &#8220;Total Disability&#8221; (as defined below), in which event the Company shall have no further obligations or liabilities under this Agreement (including, without limitation, Section 3 hereof) except to pay to the Executive or her legal representative, as the case may be, the Standard Termination Benefits. &#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total Disability</u>&#8221; shall&#160;mean a determination by the Company, that, because of a medically determinable disease, condition, injury or other physical or mental disability, the Executive is unable to substantially perform the essential duties of the Executive required hereby with or without reasonable accommodation, and that such disability is determined or reasonably expected to last for a period of twelve weeks in a twelve-month period unless a longer period is required by applicable law. &#160;This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation by the Executive for Good Reason</u>. &#160;The Executive shall be able to terminate this Agreement for Good Reason by providing written notice of termination to the Company within thirty (30) days after expiration of the cure period described in the last sentence of this Section 4(g). &#160;For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; means, with respect to the Executive, in each case to the extent not consented by the Executive: (i) a material diminution in</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Executive&#8217;s base salary (unless applied proportionately to all similarly situated executives), (ii) assignment to a primary worksite different than described in Section 1(b) of this Agreement, subject to the travel requirements set forth in Section 1(c) of this Agreement; (iii) a material violation of this Agreement or any other material agreement between the Executive and the Company, by the Company; (iv) a material reduction in the Executive&#8217;s duties, authority, or responsibilities relative to the Executive&#8217;s duties, authority, or responsibilities as the Company&#8217;s Chief Medical Officer; provided that the Executive shall not have Good Reason unless the Executive shall have provided the Company written notice describing such violation in sufficiently reasonable detail for the Company to understand the breach alleged to have occurred, with such notice provided to the Company no later than ten (10) days after the alleged breach first occurs, and the Company shall fail to cure such alleged breach within thirty (30) days after the Executive has provided the Company the required notice.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation by the Executive without Good Reason</u>. &#160;The employment of the Executive hereunder (and this Agreement) may be terminated, at the option of the Executive, without Good Reason, upon thirty (30) days&#8217; prior written notice from the Executive to the Company, in which event the Company shall have no further obligations or liabilities under this Agreement (including, without limitation, Section 3 hereof) except to pay to the Executive the Standard Termination Benefits.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Standard Termination Benefits in the Event of Separation from Employment</u>. &#160;In the event that the Executive separates from employment for any reason or no reason, the Company shall pay to the Executive: (i) accrued and unpaid Base Salary in accordance with Section 3(a) hereof; (ii) any unreimbursed expenses payable in accordance with Section 4 hereof; (iii) any earned but unpaid annual bonus from a prior fiscal year; and (iv) any amounts payable under any of the benefit plans of the Company in which the Executive was a participant in accordance with applicable law and the terms of those plans (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Standard Termination Benefits</u>&#8221;). Payment under this Section 4(i) shall be made within the time limits set by applicable law.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:14.4pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance</u>. &#160;If the Company terminates the Executive&#8217;s employment without Cause or the Executive resigns for Good Reason, in either case provided the Executive executes and does not revoke a Separation Agreement in a form acceptable to the Company, the Executive shall receive, in addition to the Standard Termination Benefits: (i) an amount equal to the Executive&#8217;s then current Base Salary for nine (9) months (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Period</u>&#8221;), less all applicable withholdings and deductions paid in equal installments in accordance with the Company&#8217;s regular payroll dates, (ii) a pro rata share of any bonus earned by the Executive during the fiscal year in which Executive&#8217;s termination occurs, based on actual attainment of metrics upon which the bonus is calculated (as recommended by the Compensation Committee and determined by the Board), with the proration based on the number of days worked during the fiscal year paid in a lump sum at the time the Company pays bonuses to similarly-situated employees; and (iii) provided Executive elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company will pay the full cost of this benefit for the Severance Period. &#160; Notwithstanding the foregoing, timing of payments under this Section 4(j) shall be subject to Section 7 hereof (relating to Section 409A of the Internal Revenue Code of 1986, as amended).</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:14.4pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation After a Sale Event</u>. &#160; If the Company terminates the Executive&#8217;s employment without Cause during the period commencing one (1) month prior or twelve (12) months after a &#8220;Sale Event&#8221; (as defined in the Plan), or the Executive terminates employment with the Company for Good Reason within twelve (12) months after a &#8220;Sale Event&#8221; (as defined in the Plan), provided the Executive executes and does not revoke a Separation Agreement in a form acceptable to the Company, the Executive shall receive, in addition to Standard Termination Benefits (i) an amount equal to the Executive&#8217;s then current Base Salary for twelve (12) months (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale Event Severance Period</u>&#8221;), less all applicable withholdings and deductions paid in equal installments in accordance with the Company&#8217;s regular payroll dates, (ii) an amount equal to the target bonus for which Executive would have been eligible during the Company fiscal year in which the Executive terminates employment, within thirty (30) days of Executive&#8217;s execution of a Separation Agreement, (iii) vesting of any unvested time-vested equity awards held by the Executive at such time; and (iv) provided Executive elects continuation coverage for health insurance under COBRA, the Company will pay the full cost of this benefit for the Sale Event Severance Period. &#160;Notwithstanding the foregoing, timing of payments under this Section 4(k) shall be subject to Section 7 hereof (relating to Section 409A of the Internal Revenue Code of 1986, as amended).</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Intellectual Property Rights</u>. &#160;In consideration of her employment, the Executive agrees to be bound by this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u>.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. The Executive agrees to assign, and hereby assigns, to the Company all of her rights in any Inventions (as hereinafter defined) (including all Intellectual Property Rights (as hereinafter defined) therein or related thereto) that are made, conceived or reduced to practice, in whole or in part and whether alone or with others, by her during her employment by, or service with, the Company or which arise out of any activity conducted by, for or under the direction of the Company (whether or not conducted at the Company&#39;s facilities, working hours or using any of the Company&#39;s assets), or which are useful with, or relate directly or indirectly to, any Company Interest (as defined below). The Executive will promptly and fully disclose and provide all of the Inventions described above (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assigned Inventions</u>&#8221;) to the Company.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assurances</u>. &#160;The Executive hereby agrees, during the Term and thereafter, to further assist the Company, at the Company&#8217;s expense, to evidence, record and perfect the Company&#8217;s rights in and ownership of the Assigned Inventions, to perfect, obtain, maintain, enforce and defend any rights specified to be so owned or assigned and to provide and execute all documentation necessary to effect the foregoing.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Interest</u>&#8221; means any business of the Company or any product, service, Invention or Intellectual Property Right that is used or under consideration or development by the Company. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights</u>&#8221; means any and all intellectual property rights and other similar proprietary rights in any jurisdiction, whether registered or unregistered, and whether owned or held for use under license with any third party, including all rights and interests pertaining to or deriving from: (a) patents and patent applications, reexaminations, extensions and counterparts claiming property therefrom; inventions, invention disclosures, discoveries and improvements, whether or not patentable; (b) computer software and firmware, including data files, source code, object code and software-related specifications and documentation; (c) works of authorship, whether or not copyrightable; (d) trade secrets (including those trade secrets defined in</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Uniform Trade Secrets Act and under corresponding statutory law and common law), business, technical and know-how information, non-public information, and confidential information and rights to limit the use of disclosure thereof by any person; (e) trademarks, trade names, service marks, certification marks, service names, brands, trade dress and logos and the goodwill associated therewith; (f) proprietary databases and data compilations and all documentation relating to the foregoing, including manuals, memoranda and record; (g) domain names; and (h) licenses of any of the foregoing; including in each case any registrations of, applications to register, and renewals and extensions of, any of the foregoing with or by any governmental authority in any jurisdiction. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invention</u>&#8221; means any products, process, ideas, improvements, discoveries, inventions, designs, algorithms, financial models, writings, works of authorship, content, graphics, data, software, specifications, instructions, text, images, photographs, illustration, audio clips, trade secrets and other works, material and information, tangible or intangible, whether or not it may be patented, copyrighted or otherwise protected (including all versions, modifications, enhancements and derivative work thereof).</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictive Covenants</u>. &#160;The Executive acknowledges and agrees that she has and will have access to secret and confidential information of the Company, its affiliates, and its subsidiaries (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221;) and that the following restrictive covenants are necessary to protect the interests and continued success of the Company. As used in this Agreement, Confidential Information includes, without limitation, all information of a technical or commercial nature (such as research and development information, patents, trademarks and copyrights and applications thereto, formulas, codes, computer programs, software, methodologies, processes, innovations, software tools, know-how, knowledge, designs, drawings specifications, concepts, data, reports, techniques, documentation, pricing information, marketing plans, customer and prospect lists, trade secrets, financial information, salaries, business affairs, suppliers, profits, markets, sales strategies, forecasts and personnel information), whether written or oral, relating to the business and affairs of the Company, its customers and/or other business associates which has not been made available to the general public.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. The Executive shall not disclose any Confidential Information to any person or entity at any time during the Term or after the separation of Executive from employment with the Company.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Solicitation/Non-Interference</u>. &#160;The Executive agrees that while the Executive is employed by the Company and for an additional one (1) year after the separation of Executive from employment with the Company, the Executive shall not (and shall cause any entity controlled by the Executive not to), directly or indirectly use any Company trade secret and/or Confidential Information to: (i) solicit, request or otherwise attempt to induce or influence, directly or indirectly, any present client, distributor, licensor or supplier, or prospective client, distributor, licensor or supplier, of the Company, or other persons sharing a business relationship with the Company, to cancel, limit or postpone their business with the Company, or otherwise take action which might cause a financial disadvantage of the Company; or (ii) hire or solicit for employment, directly or indirectly, or induce or actively attempt to influence, any employee, officer, director, agent, contractor or other business associate of the Company, to terminate her or her employment or discontinue such person&#8217;s consultant, contractor or other business association with the Company. &#160;For purposes of this Agreement, the term &#8220;prospective client&#8221;</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shall mean any person, group of associated persons or entity whose business the Company has directly solicited within the one-year period prior to the termination of her employment.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Disparagement</u>. &#160;Executive agrees that she will not in any way disparage the Company, including current or former officers, directors and employees, nor will she make or solicit any comments, statements or the like to the media or to others that may be considered to be disparaging, derogatory or detrimental to the good name or business reputation of the Company. &#160;The Company agrees that after Executive&#8217;s separation from employment, its officers and directors will not in any way disparage Executive or make or solicit any comments, statements or the like to the media or to others that is disparaging, derogatory or detrimental to the good name or business reputation of Executive.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If the Company, in its reasonable discretion, determines that the Executive violated any of the restrictive covenants contained in this Section 6, the applicable restrictive period shall be increased by the period of time from the commencement of any such violation until the time such violation shall be cured by the Executive to the satisfaction of the Company. &#160;Executive agrees that a violation of any of the restrictive covenants contained in this Section 6 shall constitute grounds for forfeiture of any equity-based awards granted to Executive by the Company (regardless of the extent to which Executive has vested in such awards), and grounds for the Company to recoup from the Executive any proceeds of equity-based awards granted to Executive by the Company.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>In the event that either any scope or restrictive period set forth in this Section 6 is deemed to be unreasonably restrictive or unenforceable in any court proceeding, the scope and/or restrictive period shall be reduced to equal the maximum scope and/or restrictive period allowable under the circumstances and applicable law.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>The Executive acknowledges and agrees that in the event of a breach or threatened breach of the provisions of this Section 6 by the Executive, the Company may suffer irreparable harm and, therefore, in advance of arbitration, the Company shall be entitled to seek immediate injunctive relief restraining the Executive from such breach or threatened breach of the restrictive covenants contained in this Section 6 in a court of competent jurisdiction. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to it in arbitration for such breach or threatened breach, including the recovery of damages from the Executive. The Company acknowledges and agrees that in the event of a breach or threatened breach of the provisions of this Section 6 by the Company, the Executive may suffer irreparable reputation harm and, therefore, the Executive shall be entitled to seek immediate injunctive relief restraining the Company from such breach or threatened breach of the restrictive covenants contained in this Section 6. Nothing herein shall be construed as prohibiting the Executive from pursuing any other remedies available to her for such breach or threatened breach, including the recovery of damages from the Company.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Under the federal Defend Trade Secrets Act of 2016 (18 U.S.C. &#167;&#160;1833(b)), &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221; Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167;&#160;1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. &#167;&#160;1833(b). Accordingly, the parties to this Agreement have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. The parties also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 409A and 280G of the Internal Revenue Code</u>.</p></td></tr></table><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation from Service</u>. &#160;Notwithstanding anything in this Agreement to the contrary, to the extent that any severance or other payments or benefits paid or provided to Executive, if any, under this Agreement are considered deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221;) and the final regulations and any guidance promulgated thereunder (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u>&#8221;) (such payments, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Payments</u>&#8221;), then to the extent required by Section 409A, no Deferred Payments will be payable unless Executive&#8217;s termination of employment also constitutes a &#8220;separation from service,&#8221; as defined in Treasury Regulations Section 1.409A-1(h) (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation from Service</u>&#8221;). Similarly, no Deferred Payments payable to Executive, if any, under this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulations Section 1.409A-1(b)(9) will be payable until Executive has a Separation from Service. For clarity, if Executive&#8217;s employment with the Company is terminated by Executive or the Company (including, without limitation, by resignation) in a manner entitling Executive to Severance Benefits, but the Executive does not incur a Separation from Service, then any severance payments or benefits that are Deferred Payments and that are not immediately payable under this Section 7(a) will instead be paid to Executive when Executive incurs a Separation from Service, as if termination of employment occurred on such date notwithstanding that Executive may no longer be employed under this Agreement.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Delay</u>. &#160;If, at the time of Executive&#8217;s Separation from Service, the Company determines that Executive is a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code and that delayed commencement of any portion of the Deferred Payments is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code (any such delayed commencement, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Delay</u>&#8221;), then that portion of the Deferred Payments will not be provided to Executive until the earlier of (i) the expiration of the six-month period measured from the date of Executive&#8217;s Separation from Service, (ii) the date of Executive&#8217;s death, or (iii) such earlier date as is permitted under Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) deferral period, all Deferred Payments deferred under the Payment Delay will be paid in a lump sum to Executive within 30 days following such expiration, and any remaining payments due under this Agreement will be paid as otherwise provided in this Agreement. The determination of whether Executive is a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code at the time of Executive&#8217;s Separation from Service will be made by the Company, in its discretion, in accordance with Section 409A (including, without limitation, Treasury Regulations Section 1.409A-1(i)). For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive the payments under this Agreement, including the severance payments and benefits, will be treated as a right to receive a series of separate payments and, accordingly, each installment payment will at all times be considered a separate and distinct payment.</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Severance Upon Execution of a Release of Claims</u>. &#160;Severance payments shall begin upon expiration of the revocation period under the general release of claims described in Sections 4(d) and (g), and the first payment made shall include amounts that would have been paid for preceding payroll periods had the general release of claims been executed and effective immediately upon the Executive&#8217;s termination of employment.&#160; Notwithstanding the foregoing, if the period for signing and revoking the general release of claims spans two calendar years, any portion of the severance that is subject to Section 409A shall not be paid until the first payroll date in the second calendar year following expiration of the revocation period.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expense Reimbursement</u>. If required for compliance with Section 409A of the Code, any expenses incurred by Executive that are reimbursed by the Company as a taxable reimbursement under this Agreement will be paid in accordance with Treasury Regulations Section 1.409A-3(i)(1)(iv) and in accordance with the Company&#8217;s standard expense reimbursement policies, but in any event on or before the last day of Executive&#8217;s taxable year following the taxable year in which Executive incurred the expenses. The amounts so reimbursed during any taxable year of Executive will not affect the amounts provided in any other taxable year of Executive, and Executive&#8217;s right to reimbursement for these amounts will not be subject to liquidation or exchange for any other benefit.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 280G of the Code</u>. &#160;Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit the Executive would receive from the Company pursuant to this Agreement or otherwise (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this Section 7(e), be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then such Payment will be equal to the Reduced Amount (as defined below). The &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduced Amount</u>&#8221; will be either (1) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (2) the entire Payment, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Executive&#8217;s receipt, on an after-tax basis, of the greatest amount of the Payment. If a reduction in the Payment is to be made, the reduction in payments and/or benefits will occur in the following order: (1) reduction of cash payments; and (2) reduction of other benefits paid to the Executive. In the event that acceleration of vesting of equity award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Executive&#8217;s equity awards. &#160;This Section 7(e) shall supersede Section 12.1 of the Plan relating to Section 280G of the Code.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attorneys&#8217; Fees</u>. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any provision of this Agreement, the prevailing party shall be entitled to reasonable attorneys&#8217; fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled pursuant to the underlying action.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>. &#160;The Executive represents and warrants to the Company that the execution, delivery and performance by the Executive of this Agreement do not conflict with or result in a violation or breach of, or constitute (with or without the giving of notice or the lapse of</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">time or both) a default under any contract, agreement or understanding, whether oral or written, to which the Executive is a party or by which the Executive is bound and that there are no restrictions, covenants, agreements or limitations on the Executive&#8217;s right or ability to enter into and perform the terms of this Agreement, and the Executive agrees to indemnify and save the Company harmless from any liability, cost or expense, including attorney&#39;s fees, based upon or arising out of any breach of this Section 9.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. &#160;The waiver by either party of any breach by the other party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by such party. No person acting other than pursuant to a resolution of the Company shall have authority on behalf of the Company to agree to amend, modify, repeal, waive or extend any provision of this Agreement.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. This Agreement shall inure to the benefit of and be enforceable by the Executive or her legal representatives, executors, administrators and heirs. The Executive may not assign any of the Executive&#8217;s duties, responsibilities, obligations or positions hereunder to any person and any such purported assignment by the Executive shall be void and of no force and effect.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;All notices, requests, demands and other communications which are required or may be given pursuant to this Agreement shall be in writing and shall be deemed to have been duly given when received if personally delivered; upon confirmation of transmission if sent by telecopy, electronic or digital transmission; the day after it is sent, if sent for next day delivery to a domestic address by recognized overnight delivery service (e.g., Federal Express); and upon receipt, if sent by certified or registered mail, return receipt requested. In each case notice shall be sent to:</p><div style="padding-left:25.2pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">If to Executive, addressed to:</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">If to the Company, addressed to:</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Molly Carr</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">[***]</font></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">[***]</font></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">iBio, Inc.</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">11750 Sorrento Valley Road, Suite 200</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">San Diego, CA 92121</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">ATTN: CFO</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">Cc: legal@ibioinc.com </p></td></tr></table></div><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or to such other place and with such other copies as either party may designate as to itself by written notice to the others.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">13.</p></td><td style="padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous.</u></p></td></tr></table><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Jurisdiction/Venue.</u> This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of California without reference to its principles regarding conflicts of law.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. The Parties mutually agree that any and all claims or controversies arising out of or relating to Employee&#8217;s employment, the termination thereof, or otherwise arising between</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Executive and the Company shall, in lieu of a jury or other civil trial, be settled by final and binding arbitration. &#160;This includes all claims between the parties. &#160;The parties also agree to submit claims to the arbitrator regarding issues of arbitrability, the validity, scope, and enforceability of this Agreement, jurisdictional issues, and any other challenges to this Agreement. &#160;Nothing in this Agreement shall be construed to prevent either party&#8217;s use of provisional remedies in aid of arbitration from a court of appropriate jurisdiction including, but not limited to, claims for temporary or preliminary injunctive relief as described in section 6. &#160;The Parties consent to the jurisdiction of the San Diego County, California courts and if the jurisdictional prerequisites exist, the United States District Court for the Southern District of California for such provisional relief. &#160;Such arbitration shall be conducted in accordance with the JAMS Employment Arbitration Rules &amp; Procedures. &#160;Any such arbitration will be conducted in San Diego, California. &#160; Except as otherwise provided by applicable law, the administrative costs of the arbitration (filing fees, cost for the arbitration site, hearing fees, arbitrator&#8217;s fee) shall be divided equally between the parties. &#160;In the event that the applicable rules of JAMS, any express statutory provisions, or controlling case law conflicts with this allocation and requires the payment of administrative costs of arbitration by the Company, the administrative costs of arbitration will be paid by the Company. &#160;The Parties agree that to the extent, if any, Employee may have a non-waivable right to file a claim or charge against the Company (such as claims for unemployment benefits, workers&#8217; compensation benefits, or charges of discrimination with the Equal Employment Opportunity Commission), this Agreement shall not be intended to waive such a right to file. &#160;If Employee or the Company arbitrates a claim against the other, neither the employee nor the Company shall, without written consent of the other party, have the right to participate in a class action in court or in arbitration, either as a class representative or a class member or join or consolidate claims with any other claims asserted by any other person. &#160;In the event any portion of this Agreement is found to be unenforceable, that portion shall not be effective and the remainder of the Agreement shall remain effective.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability.</u> In the event that any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings.</u> The descriptive headings of the several paragraphs of this Agreement are inserted for convenience of reference only and shall not constitute a part of this Agreement.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; No Oral Modifications.</u> This Agreement, together with Company&#8217;s Officer Severance Benefit Plan, if and as adopted by the Company and amended from time to time, contains the entire agreement of the parties concerning the Executive&#8217;s employment and all promises, representations, understandings, arrangements and prior agreements on such subject are merged herein and superseded hereby. Any modification to the terms of this Agreement will not be effective until signed by a duly authorized officer of the Company and the Executive.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representation by Counsel</u>. &#160;Each of the parties hereto acknowledges that: (i)&#160;it or she has read this Agreement in its entirety and understands all of its terms and conditions; (ii)&#160;it or she has had the opportunity to consult with any individuals of its or her choice regarding its or her agreement to the provisions contained herein, including legal counsel of its or her choice, and any decision not to was its or her alone; and (iii)&#160;it or she is entering into this Agreement of its or her own free will, without coercion from any source.</p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. &#160;The provisions of Sections 4 through 8, and this Section 13 shall survive termination of this Agreement.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Century Gothic';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. &#160;This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same Agreement. Delivery of facsimile or .pdf, or other electronic copies (complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com)) of signature pages for this Agreement shall be valid and treated for all purposes as delivery of the originals.</p><p style="font-family:'Century Gothic';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and the Executive has set her hand, all as of the day and year first above written.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:18.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">iBio, Inc.</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:46.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">Martin Brenner, Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">Executive</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">/s/ Molly Carr</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;">Molly Carr</p></td></tr></table></div><p style="font-family:'Century Gothic';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Century Gothic';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ibio-20260722xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.4.0.56--><!--Created on: 8/4/2026 10:58:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:16pt;font-weight:bold;">iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company&#8217;s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University and the University of Washington. Most recently, she served as Clinical Head and Associate Vice President of Lilly&#8217;s Insulin and Glucagon Franchise, where she oversaw the company&#8217;s insulin portfolio and clinical development team, including the Phase 3 program for efsitora, a once-weekly insulin, as well as programs spanning prandial insulin, nasal glucagon, biosimilars and legacy insulins. Dr. Carr earned her M.D. from Columbia University College of Physicians and Surgeons and completed her residency and fellowship in endocrinology at the University of Washington.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;Adding Molly to our leadership team is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic,&#8221; said Martin Brenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. &#8220;Her rare combination of deep scientific expertise in endocrinology and metabolic disease, together with hands-on experience leading clinical programs across all stages of development, will be invaluable as we advance IBIO-600 and IBIO-610 into their next clinical phases. Her appointment reflects iBio&#8217;s growth into a clinical-stage company and strengthens our ability to execute on our programs with the rigor and focus required to bring them closer to patients.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;The science behind iBio&#8217;s clinical candidates is closely aligned with my experience in endocrinology, obesity, muscle biology and cardiometabolic disease, and I believe these programs have the potential to meaningfully improve body composition and overall quality of life for patients,&#8221; added Dr. Carr. &#8220;I was also drawn to iBio&#8217;s clear clinical vision, highly collaborative culture, and commitment to translating differentiated science into new medicines. I look forward to working with this world-class research team to advance these candidates through the clinic.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">iBio also today announced the company has granted Dr. Carr options to purchase 430,000 shares of its common stock as inducement awards outside the company&#8217;s 2023 Omnibus Incentive Plan. The grant was</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">approved by the Compensation Committee and was made as an inducement material to the employee entering into employment in accordance with Nasdaq Lising Rule 5635(c)(4).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The option award has an exercise price of $1.40 per share, the closing price of the company&#8217;s common stock on July 31, 2026, the grant date, and has a ten-year term. The option will vest 25% on the one-year anniversary of the date of grant and after one year following the grant date, 6.25% of the options granted will vest for each additional 3 months of employment provided Dr. Carr remains employed by the company through the applicable vesting dates. These inducement awards also provide for accelerated vesting in connection with a change in control of the company or certain involuntary terminations of Dr. Carr&#8217;s employment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About iBio, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">iBio </b>(Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio&#8217;s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For more information, visit&#160;www.ibioinc.com&#160;or follow us on&#160;LinkedIn.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain statements in this press release constitute &quot;forward-looking statements&quot; within the meaning of the federal securities laws. Words such as &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;believe,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;predict,&quot; &quot;forecast,&quot; &quot;project,&quot; &quot;plan,&quot; &quot;intend&quot; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Dr. Carr leading the company&#8217;s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development; the company advancing its obesity and cardiometabolic pipeline into the clinic; Dr. Carr&#8217;s expertise and hands-on experience leading clinical programs across all stages of development being invaluable to the company as it advances IBIO-600 and IBIO-610 into their next clinical phases; Dr. Carr&#8217;s appointment reflecting iBio&#8217;s growth into a clinical-stage company and strengthening the company&#8217;s ability to execute on its programs with the rigor and focus required to bring them closer to patients; Dr. Carr&#8217;s belief that these programs have the potential to meaningfully improve body composition and overall quality of life for patients; iBio&#8217;s commitment to translating differentiated science into new medicines; the vesting of the option granted to Dr. Carr; and the accelerated vesting of the inducement award in the event of termination in connection with a change in control of the company or certain involuntary terminations of Dr. Carr&#8217;s employment. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contributions to be made by Dr. Carr; iBio&#8217;s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio&#8217;s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio&#8217;s product candidates in the marketplace and the successful development, marketing or sale of products; whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio&#8217;s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Corporate Contact:</b><br>iBio, Inc.<br><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Investor Relations<br>ir@ibioinc.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Media Contacts:</b><br>Ignacio Guerrero-Ros, Ph.D., or David Schull<br>Russo Partners, LLC<br>Ignacio.guerrero-ros@russopartnersllc.com<br>David.schull@russopartnersllc.com<br>(858) 717-2310 or (646) 942-5604</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ibio-20260722.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/4/2026 10:58:23 AM-->
<!--Modified on: 8/4/2026 10:58:23 AM-->
<xsd:schema targetNamespace="http://ibioinc.com/20260722" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ibio="http://ibioinc.com/20260722">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ibioinc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20260722_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20260722_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20260722_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ibio-20260722_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/4/2026 10:58:23 AM-->
<!--Modified on: 8/4/2026 10:58:23 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ibio-20260722.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ibio-20260722_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/4/2026 10:58:23 AM-->
<!--Modified on: 8/4/2026 10:58:23 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ibio-20260722_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/4/2026 10:58:23 AM-->
<!--Modified on: 8/4/2026 10:58:23 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20260722.xsd#DocumentDocumentAndEntityInformation" roleURI="http://ibioinc.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://ibioinc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639214379038292049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_639214379038292049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639214379038292049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639214379038292049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639214379038292049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_639214379038292049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639214379038292049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639214379038292049" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639214379038292049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_639214379038292049" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639214379038347413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639214379038347413" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639214379038347747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639214379038347747" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639214379038347747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639214379038347747" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639214379038347747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_639214379038347747" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_639214379038350472" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_639214379038350472" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_639214379038350472" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639214379038350472" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639214379038350472" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_639214379038350472" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_639214379038350472" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639214379038350472" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639214379038350472" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639214379038350472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_639214379038350472" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 22, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iBio,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2797813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11750 Sorrento Valley Road, Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">446-0027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ibio-20260722x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ibioinc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ibio-20260722.xsd</File>
    <File>ibio-20260722_def.xml</File>
    <File>ibio-20260722_lab.xml</File>
    <File>ibio-20260722_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ibio-20260722x8k.htm">ibio-20260722x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ibio-20260722x8k.htm": {
   "nsprefix": "ibio",
   "nsuri": "http://ibioinc.com/20260722",
   "dts": {
    "schema": {
     "local": [
      "ibio-20260722.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "ibio-20260722_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ibio-20260722_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibio-20260722_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ibio-20260722x8k.htm"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 20,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 19
   },
   "report": {
    "R1": {
     "role": "http://ibioinc.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20260722x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20260722x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001420720-26-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001420720-26-000014-xbrl.zip
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MANL7-MJSLLW5$6W='<=_ %!+ P04    " "P6 1=@WMU,CT%   ?.0  %0
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M+)QTW?._CO0?NNX^HWC_#XS^7U!+ P04    " "P6 1=>Z6\%KH=  #5I0
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M2#:M^!GLM0W0AH1-,*SVQ6=FO:V31^!Y&1:!KS@+ZPA ?@R#CE 2\A:=Y^<
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M&= S*7W6"MI#;FYZ(%5V>HV9D\$O"@[X=2!3,!R Y<\SY^!Q]P+FY8#SH-U
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M[#U(4IWG(N/=YWJN4OD,=U3PO\SN!S,X.M=RE^6F#YLLO/!*PS!2E0MWH*T
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M!]HJ&TUC;\#@,F1&X0\R:G>]8\)$'T@3JL$AX+()5<B^D2*T]/95-(ED@#_
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M-ZA;J:R<TQ^5!B:*T6=0D76./_957WMLND. -4#]MT[AH8'ZV14.$=&/[,-
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MV$0R[K;S$H,5.S4579=E2ZDZ@<?="A"OPUY3'-/QEE#30,/(<5]ASSH+425
M>.QPP3$7)W$-DBVC"$NONVG,&\WV/B?=H"+[$M9&885&%SEG6(M%3Q]Y^,C/
MS)0(/ 6E'C^F8ZD[C[*M:T(<&9@UU;B3?*Z]@)8HB*U#Q\A9Q6_#U\Y0(0DT
M"'PUE\F19P*[&K!+6HI"<O/>6?;4CB1AHN6$7IZ.N,EMDHW+2+/3H9@2_%!>
M*HH&4B*'[\1D_098 (=1I*CC4MB(:3(DO"]"=3]88];K^\4_=0?Q*%2?T"5B
M%Y0];FY-5V]7A/G^-988 ;B_^&JZ46\8S"T93+</TEG7IU80#870CZ#(@E5&
M#D,':%$G R!:C"2ILS!B.>SP1H57^0K/H+3J"2NK0<%@^ 01/ %\>XHC]19H
M "J/;AH';R=UM-I6Z!!@5XQ^V8*$S#UJ1N=7]TKNYM4S>(5H$0:DGJBA!/W5
M#%7%L*J?LX+67@=F!C(?$V59'^7J1OC?1!ORT<M[N/IOA_%'I ;PLE*%0/;[
M\79<$UN5OH2+\R (H1D;&^[J%E&B=B'5A@0SB@$!>M4VAW3"(88OH4AYBJK-
M %2AA)!3K3,:PB?.9,,\;LD\NNV=^JAZ A5%QRLMYUJ@<GL'. 0@[E O=6J
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MWA0Z?S@NLP7\,VUF^<__'U!+ P04    " "P6 1=-*%(*Y<.  !W+P  &
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MC#@K/.8=U"$D"7S"I,,<]4JZ5+Y'.^%HPYL&J6/_8'=_*[F_M7?_[HI1BM9
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64$L%!@     '  < U@$  &!\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ibio-20260722x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ibio-20260722.xsd" xlink:type="simple"/>
    <context id="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2026-07-22</startDate>
            <endDate>2026-07-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Tc_TRemXnGIkUyzH4eBtpI6Mw_2_1">0001420720</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Tc_tePOu3hjS0a2UTFgdSUQEg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_NYqXz3kl00CDd1ehxFMz4A">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_6Emtbrp0dUSNXqaifQ2FFw">2026-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_UnJempJLJ0uG7JTXOCyNPw">iBio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_qzNckg8bmkGO2T5aP1Gc2w">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Tc_ZXshJUAQvEOnOpLY14MsGA_1_0">001-35023</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Tc_ih291esrM0OJQA_X0O01SA_1_1">26-2797813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_jmHcOE4zJEyV21BkBPGUYw">11750 Sorrento Valley Road, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_wGyobNkuB0qSAXJ-HXgT9w">San</dei:EntityAddressCityOrTown>
    <dei:CityAreaCode
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_8HPK_as8VUeJ2PA_yabI0Q">979</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_Mgp1Unz9LUasO80oDFfP6w">446-0027</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_m7FIA7vW3UWbxYhDKOCj0Q">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_VGRLhBcZNk-Xqk_F3wzcnw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_wBZM11_RnU-XrwOSF0TjVg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_Y8yk1MX1bkmOS9Fd7dJlNw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_uEQBWNwR90O44mw7pSL4Bw">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Tc_4E7KL66C7EaTxunfVVskWw_2_1">IBIO</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_22_2026_To_7_22_2026_ztW3bRyG0ECOWGBox_fRkQ"
      id="Narr_A1rhiV3JoEaAMfhlPGBjzA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
